AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 112 min read$KMTS

Mahboob Vaseem sold $680K of KMTS

Mahboob Vaseem (Chief Financial Officer) sold 26,287 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $25.88 ($25.87–$26.33, $0.68M total) across 2 trades on 2026-08-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mahboob Vaseem
Published Aug 11, 2026, 9:56 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 10:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The disclosure updates the record of insider activity, but it does not provide new guidance, financial results, or regulatory/product developments.

02

Market read

Insider selling by an officer is disclosed, but the 10b5-1 structure suggests limited incremental information for valuation.

03

What to watch

Traders may want to check whether there are additional insider transactions around the same period or any concurrent company disclosures not mentioned here.

Relevance 4/10Novelty 3/10Timing: Filed 2026-08-11 for trades dated 2026-08-07.

Background

This is an SEC Form 4 insider transaction disclosure for KESTRA MEDICAL TECHNOLOGIES, LTD.

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

Form 4 shows CFO Mahboob Vaseem sold $680,383 of KMTS shares in open-market trades under a 10b5-1 plan.

Expected impact

Likely limited, short-lived impact unless follow-on selling or other disclosures emerge.

Evidence & confidence

The transaction is an open-market sale by an officer with a pre-arranged 10b5-1 plan, which typically reduces interpretive signal versus discretionary selling.

Market effects

Sector

No clear sector read-through from a single routine insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A 10b5-1 sale can be purely mechanical, so the market may ignore it and focus on fundamentals.

Key entities

  • issuer
    KMTS

    Kestra Medical Technologies, Ltd., the company whose shares were sold.

  • insider
    Mahboob Vaseem

    Chief Financial Officer who executed the open-market sale under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KMTS insider trading history →

Related articles

JUL 16
$KMTSMedAI 8/10

Kestra Medical Technologies Q4 Earnings Call Highlights

Kestra Medical Technologies (NASDAQ:KMTS) reported a Q4 GAAP net loss of $38.8 million and adjusted EBITDA loss of $26.7 million. CFO Vaseem Mahboob said gross margin should rise steadily and reiterated confidence in gross margins above 70% over the next few years. The company guided FY2027 revenue to $137 million, up 44% from FY2026, and added a $200 million term loan facility.

yahoo.com6 min
JUL 15
$KMTSMed

Kestra Secures $200M Non-Dilutive Financial To Strengthen Balance Sheet And Fuel Growth

Kestra Medical Technologies (KMTS) said it secured a five-year, up to $200M non-dilutive term loan facility managed by Pharmakon Advisors. A $75M tranche closed, retiring part of its $45M loan and covering fees. Remaining tranches total $125M with revenue and acquisition conditions. The loan has 48 months interest-only at 3-month SOFR plus 5.5% (3.25% floor).

rttnews.com4 min
JUL 15
$KMTSMed

Kestra Medical Technologies Ltd (KMTS) Q4 2026 Earnings Call Highlights: Record Revenue

Kestra Medical Technologies (KMTS) reported Q4 2026 call highlights. CFO Vaseem Mahboob said fiscal 2027 guidance targets $137 million revenue, driven by prescription volume growth, in-network mix, revenue cycle management improvements, and field expansion, with 44% growth. CEO Brian Webster discussed WCD guideline support, share gains, adding ~40 reps, and refinancing to cut cost of capital by 24% while keeping an M&A option open.

yahoo.com4 min
JUL 15
$KMTSMed

Kestra Medical (KMTS) Q4 2026 Earnings Call Transcript

Kestra Medical (KMTS) discussed its FY26 results on an earnings call. Revenue was $95 million for the year, up 59% from FY25, and $28.6 million in Q4, up 66% year over year. Gross margin rose to 51.4% for FY26 (up about 11 pts). The company reported 6.3k prescriptions and expanding sales territories to about 130.

yahoo.com7 min
JUL 14
$KMTSMedAI 8/10

Kestra Medical Technologies Secures Up to $200 Million of Non-Dilutive Financing

Kestra Medical Technologies (Nasdaq: KMTS) announced a five-year, non-dilutive term loan facility managed by Pharmakon Advisors. It includes $75M funded at closing (used to retire a $45M loan plus fees), $25M available through July 2027, $50M through June 2028 subject to $150M trailing revenue, and a $50M acquisition tranche. Interest is SOFR plus 5.5% with a 3.25% floor; Kestra reported $262M cash/investments as of Apr. 30, 2026.

manilatimes.net4 min